MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.21
+1.31%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 195.87x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.21x
- Price / sales
- 72.80x
- Price / cash flow
- -13.67x
Enterprise value
- Enterprise value
- $1.1B
- EV / sales
- 55.26x
- EV / EBITDA
- -8.48x
- EV / EBIT
- -7.59x
- Market cap
- $1.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026